Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

11 trials with published results (52%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 21 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

52%

11 trials in Phase 3/4

Results Transparency

61%

11 of 18 completed with results

Key Signals

11 with results100% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (4)
P 2 (5)
P 3 (11)

Trial Status

Completed18
Active Not Recruiting1
Not Yet Recruiting1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07071506Not ApplicableRecruiting

New Methods for Evaluating Preventive Migraine Treatment

NCT07497854Not Yet RecruitingPrimary

A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea

NCT06874361Not ApplicableCompletedPrimary

Cooling to Alleviate Migraine #3

NCT06695156Not ApplicableActive Not Recruiting

Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency and Functionality: A Single Arm Study

NCT07015125Not ApplicableCompleted

Evaluation of a Wearable Device for Acute Treatment of Migraines

NCT03194555Phase 2CompletedPrimary

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

NCT06245902Phase 2CompletedPrimary

An Acute Migraine Factorial Study

NCT03237845Phase 3CompletedPrimary

Safety and Efficacy in Adult Subjects With Acute Migraines

NCT03461757Phase 3CompletedPrimary

Trial in Adult Subjects With Acute Migraines

NCT03266588Phase 2CompletedPrimary

Open Label Safety Study in Acute Treatment of Migraine

NCT03235479Phase 3CompletedPrimary

Safety and Efficacy Study in Adult Subjects With Acute Migraines

NCT03061734Phase 2CompletedPrimary

Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

NCT01986270Phase 3CompletedPrimary

Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo

NCT01986088Phase 3CompletedPrimary

Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study

NCT01978496Phase 3CompletedPrimary

Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine

NCT01989936Phase 3CompletedPrimary

Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan

NCT02605174Phase 3CompletedPrimary

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

NCT02873221Phase 3CompletedPrimary

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

NCT02867709Phase 3CompletedPrimary

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02828020Phase 3CompletedPrimary

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

Scroll to load more

Research Network

Activity Timeline